The expression of YAP1 is increased in high-grade prostatic adenocarcinoma but is reduced in neuroendocrine prostate cancer.

Autor: Cheng S; Department of Biochemistry & Molecular Biology, LSU Health-Shreveport, Shreveport, LA, USA., Prieto-Dominguez N; Department of Biochemistry & Molecular Biology, LSU Health-Shreveport, Shreveport, LA, USA., Yang S; Department of Biochemistry & Molecular Biology, LSU Health-Shreveport, Shreveport, LA, USA., Connelly ZM; Department of Biochemistry & Molecular Biology, LSU Health-Shreveport, Shreveport, LA, USA., StPierre S; Department of Biochemistry & Molecular Biology, LSU Health-Shreveport, Shreveport, LA, USA., Rushing B; Department of Biochemistry & Molecular Biology, LSU Health-Shreveport, Shreveport, LA, USA., Watkins A; Department of Biochemistry & Molecular Biology, LSU Health-Shreveport, Shreveport, LA, USA., Shi L; Department of Biochemistry & Molecular Biology, LSU Health-Shreveport, Shreveport, LA, USA., Lakey M; Ochsner Clinic Foundation, New Orleans, LA, USA., Baiamonte LB; Ochsner Clinic Foundation, New Orleans, LA, USA., Fazili T; Urology Service, Overton Brooks Medical Center, Shreveport, LA, USA.; Department of Urology, LSU Health-Shreveport, Shreveport, LA, USA., Lurie A; Pathology & Laboratory Medicine Service, Overton Brooks VA Medical Center, Shreveport, LA, USA., Corey E; Department of Urology, University of Washington, Seattle, WA, USA., Shi R; Department of Medicine, LSU Health-Shreveport, Shreveport, LA, USA., Yeh Y; Department of Urology, LSU Health-Shreveport, Shreveport, LA, USA.; Pathology & Laboratory Medicine Service, Overton Brooks VA Medical Center, Shreveport, LA, USA., Yu X; Department of Biochemistry & Molecular Biology, LSU Health-Shreveport, Shreveport, LA, USA. xyu@lsuhsc.edu.; Department of Urology, LSU Health-Shreveport, Shreveport, LA, USA. xyu@lsuhsc.edu.
Jazyk: angličtina
Zdroj: Prostate cancer and prostatic diseases [Prostate Cancer Prostatic Dis] 2020 Dec; Vol. 23 (4), pp. 661-669. Date of Electronic Publication: 2020 Apr 20.
DOI: 10.1038/s41391-020-0229-z
Abstrakt: Background: After long-term androgen deprivation therapy, 25-30% prostate cancer (PCa) acquires an aggressive neuroendocrine (NE) phenotype. Dysregulation of YAP1, a key transcription coactivator of the Hippo pathway, has been related to cancer progression. However, its role in neuroendocrine prostate cancer (NEPC) has not been assessed.
Methods: Immunohistochemistry and bioinformatics analysis were conducted to evaluate YAP1 expression levels during PCa initiation and progression.
Results: YAP1 expression was present in the basal epithelial cells in benign prostatic tissues, lost in low-grade PCa, but elevated in high-grade prostate adenocarcinomas. Interestingly, the expression of YAP1 was reduced/lost in both human and mouse NEPC.
Conclusions: The expression of YAP1 is elevated in high-grade prostate adenocarcinomas but lost in NEPC.
Databáze: MEDLINE
Externí odkaz: